Oxybutynin and Metoclopramide Interaction
Drug interaction information between Oxybutynin and Metoclopramide.
Oxybutynin and Metoclopramide have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Oxybutynin and Metoclopramide. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
These two drugs have opposite effects on how your digestive system moves. Oxybutynin can block metoclopramide from doing its job of moving food through your stomach.
What To Do
Your doctor may need to check if both medications are still working effectively for you.
FDA Label Information
Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide.
Oxybutynin Also Interacts With
- Ketoconazole minor
- Erythromycin minor
- Clarithromycin minor
- Itraconazole minor
- Carbamazepine minor
Metoclopramide Also Interacts With
- Posaconazole major
- Lidocaine Topical moderate
- Rivastigmine moderate
- Tacrolimus Topical moderate
- Tranylcypromine moderate
Frequently Asked Questions
Can I take Oxybutynin and Metoclopramide together?
This is a minor interaction. Your doctor may need to check if both medications are still working effectively for you.
How serious is the interaction between Oxybutynin and Metoclopramide?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Oxybutynin and Metoclopramide interact?
These two drugs have opposite effects on how your digestive system moves. Oxybutynin can block metoclopramide from doing its job of moving food through your stomach.
Understanding the Oxybutynin and Metoclopramide Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Oxybutynin belongs to the Anticholinergic / Antispasmodic class and Metoclopramide belongs to the Prokinetic / Antiemetic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These two drugs have opposite effects on how your digestive system moves. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Oxybutynin has 7 total documented interactions on file in this dataset, and Metoclopramide has 23. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to check if both medications are still working effectively for you. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Oxybutynin or Metoclopramide based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.